Dr. Eunjung (EJ) Park is a Lead Pharmacologist in the Division of Bioequivalence II (DBII), Office of Bioequivalence, Office of Generic Drugs, CDER/FDA, where she leads bioequivalence assessments of complex generic drug products — including nasal and inhalation, and ophthalmic formulations. Her contributions include pioneering the first alternative approach for a comparative clinical endpoint study for Beclomethasone Dipropionate Metered Inhalation Aerosol.

Prior to her current role, Dr. Park served as an ORISE Fellow and Staff Fellow in the Division of Cardiovascular and Renal Products (OND), focusing on safety pharmacology, including QT prolongation and renal function. Before joining the FDA, she contributed to anticancer drug development at EntreMed, Inc. and conducted postdoctoral research at the National Cancer Institute and the University of Illinois at Chicago.

Dr. Park has authored over 30 peer-reviewed publications, multiple book chapters, and more than 50 scientific presentations at national and international conferences. She is the recipient of numerous CDER Honor Awards, FDA Awards, the Translational Safety Pharmacology Publication Award (Safety Pharmacology Society, 2018), and multiple Generic Drug Science Day Poster Awards (2023, 2025, 2026).

She holds a B.S. in Pharmacy from Ewha Womans University and an M.S. and Ph.D. in Pharmacy from Seoul National University, South Korea.